Ocean Biomedical, a biopharmaceutical company, agreed to go public via a SPAC merger with Aesther Healthcare Acquisition in a $345m deal. “The world is on the cusp of a new era in biomedicine, and we are excited to be teaming up with a biopharma company that has both cutting-edge science and an innovative business model. We think that combination will result in positive valuations and long term growth, as we continually focus on identifying and accelerating promising discoveries," Suren Ajjarapu, Aesther Chairman and CEO.